Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Safety of CAR T-Cell Therapy in Patients with Active Autoimmune Diseases: A Case Report
Autoimmune Neurology
P3 - Poster Session 3 (5:30 PM-6:30 PM)
14-003
CAR-T is now a well-established treatment for several cancers. However, the use of CAR-T is limited by immune-related adverse events (irAEs). It is unknown whether immune dysregulation disorders might increase the risk for irAEs, and whether successful use of CAR-T might ameliorate a concurrent paraneoplastic syndrome.
Describe the case of a patient with diffuse large B-cell lymphoma (DLBCL) with active paraneoplastic neuropathy at the time of chimeric antigen receptor therapy (CAR-T) who improved.
N/A

A 72-year-old woman with DLBCL treated with six cycles of R-CHOP, as well as two doses of intrathecal methotrexate, presented with progressive limb weakness and numbness over several weeks. Examination revealed 3/5 intrinsic hand muscles, 4/5 bilateral hip flexors, 2/5 left foot plantar/dorsiflexion, 1/5 in the right foot and absent patellar/Achilles reflexes bilaterally. Sensation was decreased to all modalities below the ankles.

 

EMG/NCS demonstrated severe symmetrical sensorimotor demyelinating polyneuropathy with active and chronic denervation. She received 2g/kg IVIG with limited benefit. She was refractory to additional MATRix chemotherapy. Ultimately, she proceeded with lisocabtagene maraleucel (liso-cel) CAR-T.

 

She had CRS grade 1 (fever) treated with tocilizumab and dexamethasone. She had a single drop in her ICE score to 9/10, but this resolved. She was safely discharged on post-infusion Day 8.

 

Examination was improved three months later with 4+/5 hip flexion, 4-5/5 dorsiflexion and plantarflexion bilaterally, normal patellar reflexes, absent ankle jerk. She could mobilize independently. She had no evidence of disease on PET/CT until a recurrence 8 months later successfully treated with rituximab, lenalidomide, and zanubrutinib.

We hope that our experience might open the discussion for broader use of CAR-T in oncology patients with autoimmune and paraneoplastic syndromes.
Authors/Disclosures
Alec Friedman, MD (Columbia University Irving Medical Center)
PRESENTER
Dr. Friedman has nothing to disclose.
Andrew Lipsky No disclosure on file
Christian Gordillo (Columbia University Irving Medical Center) No disclosure on file
Ran Reshef No disclosure on file
Sarah F. Wesley, MD (Columbia University College of Physicians and Surgeons) Dr. Wesley has nothing to disclose.